Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Press Releases

[Mexico City, Mexico – 12 August 2014] 
New Drug Candidate for Chagas Disease Tested in Patients in Bolivia
Phase II Trial Launched to Test Safety and Efficacy of ‘Rediscovered’ Fexinidazole in 140 Adults with Chronic Indeterminate Chagas Disease
The Drugs for Neglected Diseases initiative (DNDi) announced today at the International Congress of Parasitology (ICOPA), the launch of a Phase II drug trial to test fexinidazole, a drug shelved in the 1980s and ‘rediscovered’ by DNDi nearly a decade ago, for Chagas disease patients. The drug is also being tested in patients in Africa for two other parasitic diseases, sleeping sickness and visceral leishmaniasis.
[Español] [Português]

More

[Mexico City, Mexico – 11 August 2014] 
The Global Chagas Disease Coalition stages high-level event to encourage increased access to diagnosis and treatment of patients fighting Chagas disease
Of the 8 million people infected in the world, 1 million are Mexican
At the 2014 International Congress of Parasitology (ICOPA), the Global Chagas Disease Coalition launched the event “Let’s Raise Our Voice” to alert the world that of the 8 million patients infected with Chagas disease, 99% have not been treated. The aim of this event is to promote an alliance among governments, civil society, doctors, researchers, and patients to discuss simple actions that can be taken to boost patient access to diagnosis and treatment.
[Español] [Português]

More

[Geneva, Switzerland – 3 June 2014]
DNDi Welcomes Progress Made at WHA in R&D Financing and Coordination for Developing Country Health Needs
Overall political consensus and initial financial commitments secured during recent World Health Assembly, laying foundations for publicly-led research and development to bridge innovation of and access to essential health tools in developing countries
At the recent 67th World Health Assembly (WHA) in Geneva, a global political consensus by the Member States gave a solid ‘go-ahead’ to advance a process that began over a decade ago to ensure that research and development (R&D) for the priority health needs of developing countries benefits from global public leadership. The process, referred to as the Consultative Expert Working Group (CEWG) process, notably aims at securing sustainable financing and coordination to fundamentally link innovation and access to essential health tools. Initial financial commitments were announced by France, Switzerland, Brazil, and Kenya.

More

[Geneva, Switzerland – 22 May 2014]
DNDi Receives Support from Norwegian Agency for Development Cooperation for its Research & Development on Sleeping Sickness
The Drugs for Neglected Diseases initiative (DNDi) welcomes new public funding from the Norwegian Agency for Development Cooperation (NORAD). This grant of NOK 15 million (EUR 1.85 million), to be disbursed over three years (until 2015), will be dedicated to the development of an oral treatment for sleeping sickness, as well as to strengthen local capacities in the endemic African countries through the Human African Trypanosomiasis (HAT) Platform, a network of key regional actors in clinical research for the disease.

More

[Geneva, Switzerland – 19 May 2014]
Paediatric HIV Treatment Initiative (PHTI) to Spur Innovation and Access to Improve the Lives of Children Living with HIV
UNITAID, DNDi, and the Medicines Patent Pool Gather Global Experts, Health Ministries, and Industry Leaders in Support of the Initiative to Expedite Development and Delivery of New Antiretroviral Formulations
On the eve of the 67th World Health Assembly, Ministers of Health from over fifteen countries including Brazil, Chile, Mauritius, and South Africa; industry and global public health leaders; as well as senior representatives from the HIV/AIDS community joined UNITAID Chair Philippe Douste-Blazy at a special event last evening to urge a more coordinated response to caring for the 3.3 million children currently living with HIV. While significant progress has been made over the past 15 years in improving access to antiretroviral treatment for adults, only a quarter of children in need receive ARV therapy today. Each day, 500 children die of HIV/AIDS-related causes.
[Français

More

Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License